• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency.先天性因子 VII 缺乏症中内质网应激和未折叠蛋白反应的激活。
Thromb Haemost. 2018 Apr;118(4):664-675. doi: 10.1055/s-0038-1637690. Epub 2018 Apr 4.
2
Factor VII deficiency: Unveiling the cellular and molecular mechanisms underlying three model alterations of the enzyme catalytic domain.因子 VII 缺乏症:揭示酶催化结构域三种模型改变的细胞和分子机制。
Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):660-667. doi: 10.1016/j.bbadis.2017.12.016. Epub 2017 Dec 12.
3
A novel missense mutation close to the charge-stabilizing system in a patient with congenital factor VII deficiency.一名先天性因子VII缺乏症患者中靠近电荷稳定系统处的一种新型错义突变。
Blood Coagul Fibrinolysis. 2011 Jun;22(4):264-70. doi: 10.1097/MBC.0b013e3283447388.
4
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency.杂合性无义突变的差异功能通读导致凝血因子 VII 缺乏症的出血表型。
J Thromb Haemost. 2016 Oct;14(10):1994-2000. doi: 10.1111/jth.13443. Epub 2016 Sep 19.
5
Impaired secretion of carboxyl-terminal truncated factor VII due to an F7 nonsense mutation associated with FVII deficiency.由于与 FVII 缺乏相关的 F7 无义突变导致羧基末端截断因子 VII 的分泌受损。
Thromb Res. 2010 Mar;125(3):262-6. doi: 10.1016/j.thromres.2009.09.014. Epub 2009 Oct 12.
6
N-Glycan-calnexin interactions in human factor VII secretion and deficiency.N-糖基化与钙网织蛋白在人凝血因子 VII 分泌和缺乏中的相互作用。
Int J Biochem Cell Biol. 2019 Aug;113:67-74. doi: 10.1016/j.biocel.2019.05.017. Epub 2019 Jun 8.
7
Compound heterozygous mutations (p.Leu13Pro and p.Tyr294*) associated with factor VII deficiency cause impaired secretion through ineffective translocation and extensive intracellular degradation of factor VII.复合杂合突变(p.Leu13Pro 和 p.Tyr294*)与因子 VII 缺乏症有关,导致因子 VII 通过无效易位和广泛的细胞内降解而分泌受损。
Thromb Res. 2013 Feb;131(2):166-72. doi: 10.1016/j.thromres.2012.10.005. Epub 2012 Nov 8.
8
In vitro expression of mutant factor VII proteins and characterization of their clinical significance.体外表达突变型因子 VII 蛋白及其临床意义的研究。
Mol Med Rep. 2018 Feb;17(2):2738-2742. doi: 10.3892/mmr.2017.8158. Epub 2017 Nov 27.
9
The effect of the chemical chaperone 4-phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagulation factor FVII.化学伴侣4-苯基丁酸对凝血因子FVII的p.Q160R错义变体的分泌和活性的影响。
Cell Biosci. 2019 Aug 27;9:69. doi: 10.1186/s13578-019-0333-8. eCollection 2019.
10
Molecular Characterization of Two Homozygous Factor VII Variants Associated with Intracranial Bleeding.
Thromb Haemost. 2021 Dec;121(12):1588-1598. doi: 10.1055/a-1450-8568. Epub 2021 May 5.

引用本文的文献

1
Identification and evaluation of Pharmacological enhancers of the factor VII p.Q160R variant.凝血因子VII p.Q160R变异体的药理学增强剂的鉴定与评估。
Sci Rep. 2025 Apr 24;15(1):14315. doi: 10.1038/s41598-025-98689-3.
2
Unraveling the Molecular Pathogenesis of Protein C Deficiency-Associated VTE: Insights from Protein C Mutations C238G and R189W in Thai Patients.解析蛋白C缺乏相关静脉血栓形成的分子发病机制:来自泰国患者蛋白C突变C238G和R189W的见解
Thromb Haemost. 2025 Jun;125(6):533-544. doi: 10.1055/a-2408-9529. Epub 2024 Sep 3.
3
The effect of the chemical chaperone 4-phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagulation factor FVII.
化学伴侣4-苯基丁酸对凝血因子FVII的p.Q160R错义变体的分泌和活性的影响。
Cell Biosci. 2019 Aug 27;9:69. doi: 10.1186/s13578-019-0333-8. eCollection 2019.

先天性因子 VII 缺乏症中内质网应激和未折叠蛋白反应的激活。

Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency.

机构信息

Department of Haematology, Oslo University Hospital, Oslo, Norway.

Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.

出版信息

Thromb Haemost. 2018 Apr;118(4):664-675. doi: 10.1055/s-0038-1637690. Epub 2018 Apr 4.

DOI:10.1055/s-0038-1637690
PMID:29618153
Abstract

Congenital factor (F) VII deficiency is a bleeding disorder caused by a heterogeneous pattern of mutations in the gene. Protein misfolding due to mutations is a strong candidate mechanism to produce the highly represented type I FVII deficiency forms, characterized by a concomitant deficiency of FVII antigen and activity. Misfolded proteins can accumulate within the endoplasmic reticulum (ER) causing ER stress with subsequent activation of the unfolded protein response (UPR). So far, there are limited data on this important issue in FVII deficiency. In this study, we chose as candidate FVII model mutations, the p.Q160R, p.I289del and p.A354V-p.P464Hfs, which are all associated with severe to moderate type I FVII deficiency. In vitro expression of the recombinant (r) mutants rFVII-160R, rFVII-289del or rFVII-354V-464Hfs, which are characterized by either amino acid substitution, deletion, or by an extended carboxyl terminus, demonstrated inefficient secretion of the mutant proteins, probably caused by intracellular retention and association with ER chaperones. Both ER stress and UPR were activated following expression of all FVII mutants, with the highest response for rFVII-289del and rFVII-354V-464Hfs. These data unravel new knowledge on pathogenic mechanisms leading to FVII deficiency, and support the investigation of pharmaceutical modulators of ER stress and UPR as therapeutic agents.

摘要

先天性因子 VII 缺乏症是一种出血性疾病,由基因中的杂合突变引起。由于突变导致的蛋白质错误折叠是产生高度代表性的 I 型 FVII 缺乏症形式的强有力候选机制,其特征是同时缺乏 FVII 抗原和活性。错误折叠的蛋白质可以在内质网(ER)内积累,导致 ER 应激,随后激活未折叠蛋白反应(UPR)。迄今为止,关于 FVII 缺乏症的这个重要问题的数据有限。在这项研究中,我们选择了 p.Q160R、p.I289del 和 p.A354V-p.P464Hfs 作为候选 FVII 模型突变,这些突变均与严重至中度 I 型 FVII 缺乏症相关。重组(r)突变体 rFVII-160R、rFVII-289del 或 rFVII-354V-464Hfs 的体外表达,其特征分别为氨基酸取代、缺失或羧基末端延长,表明突变蛋白的分泌效率低下,可能是由于细胞内滞留和与 ER 伴侣结合所致。所有 FVII 突变体表达后均激活了 ER 应激和 UPR,rFVII-289del 和 rFVII-354V-464Hfs 的反应最为强烈。这些数据揭示了导致 FVII 缺乏症的致病机制的新知识,并支持了对 ER 应激和 UPR 的药物调节剂作为治疗剂的研究。